Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of ANA598 Administered With Pegylated Interferon and Ribavirin in Genotype 1 Patients With Chronic Hepatitis C Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2016
Price :
$35
*
At a glance
- Drugs Setrobuvir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 23 Jul 2013 Status changed from active, no longer recruiting to completed, as reported by Clinicaltrials.gov record NCT01903954.
- 23 Jul 2013 Status changed from active, no longer recruiting to completed, as reported by Clinicaltrials.gov record NCT01903954.
- 23 Jul 2013 New source identified and integrated: ClinicalTrials.gov record NCT01903954.